Lantheus (LNTH) investor relations material

Strategic priorities and product development

• Focus on expanding PYLARIFY, the leading prostate cancer imaging agent, with the rollout of the TruVu formulation to increase dose yield and reach more patients, starting at the end of this year and continuing into 2027.

• Neuraceq, an amyloid imaging agent, is being rapidly expanded nationwide, leveraging existing manufacturing infrastructure, with a 50% increase in facilities over the past year.

• Pipeline includes late-stage diagnostic agents under FDA review, such as MK-6240 (tau imaging), PNT2003 (therapeutic), and RM2 (targeting gastrin-releasing peptide receptor), with pivotal trials planned.

• Capital allocation is focused on advancing late-stage assets and making strategic decisions on product development priorities through 2027.

Manufacturing, supply chain, and workflow integration

• Nearly 70 manufacturing sites support broad product availability, with TruVu enabling higher activity per batch and extended shipping distances.

• TruVu's FDA approval in March enables a phased rollout, starting regionally at the end of this year, with full U.S. coverage expected in Q1 2025, pending reimbursement and coding readiness.

• Workflow for imaging techs and radiologists remains unchanged with TruVu, ensuring seamless integration and transparency for customers.

• Manufacturing capacity is being expanded in line with industry investment, with careful management to avoid bottlenecks and maximize throughput.

Market trends and growth drivers

• PSMA PET scans have reached about 80% market penetration, with the addressable market projected to grow from $500 million to $3.5 billion by 2030, driven by increased use in patient selection for therapy and rising prostate cancer incidence.

• The MIRROR phase IV study may expand guideline-based use of PYLARIFY to lower-risk patients, contributing modestly to growth.

• Imaging centers are extending operating hours to meet demand, with F-18 agents like PYLARIFY preferred for faster scans and higher throughput compared to gallium agents.